Vesicare is the first overactive bladder treatment at an approved dose to show a statistically significant increase in warning time before urination Christchurch, New Zealand – December 1, 2006 – ...

Solifenacin succinate 1mg/mL; oral susp; orange-flavor. Take once daily, followed by liquid (eg, water or milk). Avoid taking at the same time with food or other drinks. Missed dose: take as soon as ...

WALTHAM, Mass., April 3, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on ...

Nov. 23, 2004 — The U.S. Food and Drug Administration (FDA) has approved solifenacin succinate for the treatment of overactive bladder, erlotinib as second-line therapy for locally advanced or ...

The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.

The Scottish Medicines Consortium, Scotland’s equivalent to the National Institute for Health and Clinical Excellence in England and Wales, has decided to back the use of Astellas Pharma’s Vesicare ...

Hi Doc Thanks for the reply to my earlier question about taking Vesicare & Trepiline for my bladder problems. I would just like to please know could I not change the dosage of Trepiline to, say, 25mg ...

Camber is introducing solifenacin succinate tablets, which are the generic of Vesicare. The medication is used to treat symptoms of overactive bladder, such as frequent or urgent urination and ...

Teva Pharmaceutical announced the launch of its generic version of Vesicare. The tablets, which are available in 5 mg and 10 mg in the United States, are a solifenacin succinate indicated for the ...

Astellas tapped independent agency Roska Healthcare as consumer agency-of-record for Astellas’ new overactive bladder pill, Myrbetriq (mirabegron). The agency announced the win in August, just over a ...

We're accustomed to animated characters in our drug advertising. That cheerful, buzzing Nasonex bee. The gently fluttering Lunesta moth. The droopy, sad little blob that so needs Zoloft. But a perky .

Strategic Challenge: How do you become the #1 brand in a category no one wants to talk about? Let's face it…people don't want to talk about their bladder, let alone their overactive bladder (OAB) and ...